Sensei Biotherapeutics (NASDAQ:FTH) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of Sensei Biotherapeutics (NASDAQ:FTH) from a hold rating to a sell rating in a report released on Saturday,Wall Street Zen reports.

Several other analysts have also recently issued reports on FTH. Oppenheimer initiated coverage on Sensei Biotherapeutics in a report on Tuesday, July 28th. They issued an “outperform” rating and a $60.00 target price for the company. Guggenheim started coverage on shares of Sensei Biotherapeutics in a research report on Wednesday, September 16th. They set a “buy” rating and a $70.00 price target on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Sensei Biotherapeutics in a report on Thursday, June 4th. TD Cowen began coverage on shares of Sensei Biotherapeutics in a research report on Wednesday, September 9th. They set a “buy” rating for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research note on Monday, September 14th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $56.25.

Sensei Biotherapeutics Trading Down 0.8%

Shares of Sensei Biotherapeutics stock opened at $27.77 on Friday. The firm has a market cap of $717.58 million, a PE ratio of -0.20 and a beta of -0.28. The business’s 50 day moving average is $32.06. Sensei Biotherapeutics has a 1-year low of $7.45 and a 1-year high of $42.14.

Sensei Biotherapeutics (NASDAQ:FTH) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($2.84) EPS for the quarter, beating the consensus estimate of ($5.04) by $2.20. As a group, research analysts forecast that Sensei Biotherapeutics will post -13.69 earnings per share for the current fiscal year.

Insider Activity at Sensei Biotherapeutics

In other Sensei Biotherapeutics news, CFO Brian C. Stephenson purchased 5,000 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The shares were acquired at an average price of $23.50 per share, with a total value of $117,500.00. Following the purchase, the chief financial officer directly owned 46,688 shares in the company, valued at approximately $1,097,168. This trade represents a 11.99% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. 7.00% of the stock is currently owned by company insiders.

Institutional Trading of Sensei Biotherapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Citadel Advisors LLC purchased a new position in Sensei Biotherapeutics during the second quarter worth about $307,000. Renaissance Technologies LLC lifted its holdings in shares of Sensei Biotherapeutics by 178.2% in the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock worth $1,010,000 after acquiring an additional 20,525 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after acquiring an additional 32,719 shares during the last quarter. Stempoint Capital LP purchased a new position in shares of Sensei Biotherapeutics during the 1st quarter worth approximately $4,188,000. Finally, Alyeska Investment Group L.P. purchased a new position in shares of Sensei Biotherapeutics during the 2nd quarter worth approximately $3,610,000. 10.50% of the stock is currently owned by hedge funds and other institutional investors.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for the treatment of cancer. The company’s research is centered on activating and directing the immune system to recognize and attack tumor cells.

Sensei’s technology platform is designed to generate Immune Modulating Antibodies, or IMAs, which are intended to stimulate anti-tumor immune responses by targeting mechanisms involved in immune regulation. Its development programs have included antibody-based therapies evaluated for solid tumors, including programs studied in combination with established checkpoint inhibitors.

The company was founded in 2018 and is based in Cambridge, Massachusetts.